Literature DB >> 22014882

Serum 25 OH vitamin D concentrations and calcium intake are low in patients with prostate cancer.

Mariela Varsavsky1, Rebeca Reyes-García, María Cortés-Berdonces, Antonia García-Martin, Pedro Rozas-Moreno, Manuel Muñoz-Torres.   

Abstract

OBJECTIVE: To evaluate dietary calcium intake (DCI) and vitamin D serum concentrations in patients with prostate cancer.
METHODS: We conducted a cross-sectional study including 91 subjects with prostate cancer. We determined DCI by a questionnaire, 25 OH vitamin D levels and bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA).
RESULTS: According to current guidelines (1000 mg/day), calcium intake was low in patients with prostate cancer (394±201 mg/day). Twenty-two percent (20) of patients had adequate levels of vitamin D, whereas 29.7% (27) of patients were vitamin D deficient and 48.3% (44) were classified as vitamin D insufficiency. Vitamin D levels were not different in patients with or without androgen-deprivation therapy. There were no correlation between DCI, 25 OH vitamin and BMD.
CONCLUSIONS: In summary, in our group of prostate cancer patients DCI was low and vitamin D deficiency is highly prevalent. Although this is a common condition in other populations, in this group of patients especially prone to osteoporosis could have more relevance. Additional research is needed to establish the consequences of low calcium intake and vitamin D deficiency in prostate cancer patients.
Copyright © 2011 SEEN. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22014882     DOI: 10.1016/j.endonu.2011.07.007

Source DB:  PubMed          Journal:  Endocrinol Nutr        ISSN: 1575-0922


  2 in total

Review 1.  [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].

Authors:  Stefan Kudlacek; Thomas Puntus
Journal:  Wien Med Wochenschr       Date:  2012-08-09

2.  Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy.

Authors:  Maria E Suarez-Almazor; Prashanth Peddi; Ruili Luo; Hoang T Nguyen; Linda S Elting
Journal:  Support Care Cancer       Date:  2013-10-22       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.